文献速递神经肿瘤小儿神经外科与脑积水

PNOC015:对新诊断弥漫性内生性脑桥胶质瘤患儿重复采用对流增强递送MTX110(水性帕比司他)

PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.
PubMed 文献 · Neuro Oncol · 2023-01-01

该研究旨在确定对新诊断且完成局灶放疗的弥漫性内生性脑桥胶质瘤(DIPG)患儿,通过对流增强递送(CED)给予MTX110(水性帕比司他)的安全性、耐受性和分布。2018年5月至2020年3月纳入7例患儿,共接受48次CED输注,中位总生存期为26.1个月(95%CI 14.8-未达到),结论认为重复CED联合钆特醇实时成像对DIPG患儿可耐受,中位OS与历史数据相比有利,结果支持在更大队列中进一步研究该策略。

要点

  • MTX110经CED联合钆特醇实时MRI监测在DIPG患儿中可耐受。
  • 中位总生存期26.1个月(95%CI 14.8-未达到),与历史数据相比有利。
  • 3例出现剂量限制性毒性,4例次3级治疗相关不良事件,多为短暂新发或加重的神经功能异常。

核心结论

  • 重复CED递送MTX110联合钆特醇实时成像对DIPG患者可耐受。
  • 中位总生存期26.1个月(95%CI 14.8-未达到),与DIPG患儿历史数据相比有利。
  • 结果支持在更大队列中进一步研究该策略。

研究设计与样本

  • 研究为加速剂量递增设计,纳入完成局灶放疗后2-21岁的DIPG患者。
  • CED递送MTX110联合钆特醇,共7个剂量水平(30-90 µM;体积从3 mL至连续2次6 mL)。
  • 每4-8周重复CED,实时MRI监测输注液分布。
  • 2018年5月至2020年3月共纳入7例患者,接受48次CED输注,中位年龄8岁(范围5-21岁)。

主要发现

  • 3例患者出现剂量限制性毒性,观察到4例次3级治疗相关不良事件。
  • 大多数毒性为短暂新发或加重的神经功能异常。
  • 中位总生存期为26.1个月(95%CI 14.8-未达到)。
  • 无进展生存期为4-14个月(中位7个月)。
  • 每例患者联合CED输注的肿瘤覆盖累积百分比范围为35.6%至81.0%。

关键数值与推荐

  • 剂量水平为30-90 µM,体积从3 mL至连续2次6 mL。
  • 重复CED每4-8周进行。
  • 生活质量评估在基线、治疗期间每3个月和治疗结束时进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to determine the safety, tolerability, and distribution of MTX110 (aqueous panobinostat) delivered by convection-enhanced delivery (CED) in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) who completed focal radiation therapy (RT). METHODS: Patients with DIPG (2-21 years) were enrolled after RT. CED of MTX110 combined with gadoteridol was completed across 7 dose levels (DL) (30-90 µM; volumes ranging from 3 mL to 2 consecutive doses of 6 mL). An accelerated dose escalation design was used. Distribution of infusate was monitored with real-time MR imaging. Repeat CED was performed every 4-8 weeks. Quality-of-life (QoL) assessments were obtained at baseline, every 3 months on therapy, and end of therapy. RESULTS: Between May 2018 and March 2020, 7 patients who received a total of 48 CED infusions, were enrolled (median age 8 years, range 5-21). Three patients experienced dose-limited toxicities. Four grade 3 treatment-related adverse events were observed. Most toxicities were transient new or worsening neurologic function. Median overall survival (OS) was 26.1 months (95% confidence interval: 14.8-not reached). Progression-free survival was 4-14 months (median, 7). Cumulative percentage of tumor coverage for combined CED infusions per patient ranged from 35.6% to 81.0%. Increased CED infusions were negatively associated with self-reported QoL assessments. CONCLUSION: Repeat CED of MTX110 with real-time imaging with gadoteridol is tolerable for patients with DIPG. Median OS of 26.1 months compares favorably with historical data for children with DIPG. The results support further investigation of this strategy in a larger cohort.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Mueller S, Kline C, Stoller S, et al. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2023. PMID: 37318058. doi:10.1093/neuonc/noad105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。